GML-1

GML-1
Identifiers
IUPAC name
  • N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide
PubChem CID
Chemical and physical data
FormulaC22H19N3O
Molar mass341.4 g·mol−1
 ☒NcheckY (what is this?)  (verify)

GML-1 is a TSPO (peripheral benzodiazepine receptor) ligand with anxiolytic activity.[1] Its binding affinity (Ki value) to TSPO is comparable with PK11195. GML-1 is selective for TSPO versus the central benzodiazepine receptor (CBR, GABAA receptor). The compound GML-1 was the most active of a series of 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamides, and its anxiolytic effects were examined using the open field test (OFT) and the elevated plus maze (EPM) test. The EPM test is a general anxiety test measuring the time spent by animals in the open or the enclosed arms. When compound was administered to CD-1 mice at the dose of 1.0 mg/kg, it significantly increased the percentage of open arm entries and the time spent in the open arms. GML-1 is a potential antianxiety agent.

The TSPO-mechanism of anxiolytic action of GML-1 was proved by inhibitor analysis with TSPO antagonist PK11195 that blocks effect of GML-1.[1]

The involvement of neurosteroids in the mechanism of action of GML-1 was confirmed by co-administration of GML-1 with neurosteroid synthesis inhibitors. The anxiolytic effect of GML-1 in elevated plus-maze tests was completely blocked by the neurosteroidogenic-enzyme inhibitors trilostane and finasteride.[2]

The tablet dosage form of GML-1 was developed and showed pronounced anxiolytic activity after intragastric administration in rats in a wide range of doses. [3]

References

  1. 1 2 Mokrov GV, Deeva OA, Gudasheva TA, Yarkov SA, Yarkova MA, Seredenin SB (Jul 2015). "Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamides". Bioorganic & Medicinal Chemistry. 23 (13): 3368–78. doi:10.1016/j.bmc.2015.04.049. PMID 25937237.
  2. ↑ Yarkova MA, Mokrov GV, Gudasheva TA, Seredenin SB (Nov 2016). "Novel Pyrrolo[1,2-a]Pyrazines (TSPO Ligands) with Anxiolytic Activity Dependent on Neurosteroid Biosynthesis". Pharmaceutical Chemistry Journal. 50 (8): 501–4. doi:10.1007/s11094-016-1476-0. S2CID 35338758.
  3. ↑ Yarkova MA, Blynskaya EV, Yudina DV, Mokrov GV, Gudasheva TA, Alekseev KV (Jul 2019). "Development and Study of Anxiolytic Effect of GML-1 Tablet Dosage Form". Pharmaceutical Chemistry Journal. 53 (4): 342–346. doi:10.1007/s11094-019-02003-1. S2CID 195878442.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.